mallotojaponin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mallotojaponin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	122659
CHEMBL ID	487405
MeSH ID	M0191279

Synonyms (11)

Synonym
86828-07-1
1-[3-[[3-acetyl-2,4,6-trihydroxy-5-(3-methylbut-2-enyl)phenyl]methyl]-2,6-dihydroxy-4-methoxy-5-methyl-phenyl]ethanone
mallotojaponin
3-(3,3-(dimethylallyl)-5-(3-acetyl-2,4-dihydroxy-5-methyl-6-methoxybenzyl)-phloracetophenone)
CHEMBL487405
ethanone, 1-(3-((3-acetyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl)-2,4,6-trihydroxy-5-(3-methyl-2-butenyl)phenyl)-
ccris 7218
3-(3,3-dimethylallyl)-5-(3-acetyl-2,4-dihydroxy-5-methyl-6-methoxybenzyl)phloroacetophenone
DTXSID10235846
c24h28o8
1-[3-[(3-acetyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl]-2,4,6-trihydroxy-5-(3-methyl-2-butenyl)phenyl]ethanone

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay ID	Title	Year	Journal	Article
AID332829	Antitumor activity against mouse solid EAC cells xenografted in ddY mouse assessed as tumor weight at 7 mg/kg, ip qd for 3 to 8 days measured after 10 days
AID332827	Toxicity in ddY mouse xenografted with mouse solid Ehrlich carcinoma cells assessed as mortality at 7 mg/kg, ip qd for 3 to 8 days measured after 10 days
AID338780	Cytotoxicity against mouse B16 cells
AID400039	Cytotoxicity against human KB cells
AID460579	Inhibition of HIV reverse transcriptase at 25 ug/mL	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols.
AID400040	Cytotoxicity against mouse L5178Y cells
AID338774	Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids at 2 ug/ml after 1 hr
AID338779	Cytotoxicity against human PC13 cells
AID338782	Cytotoxicity against mouse P388 cells
AID332825	Cytotoxicity against mouse L5178Y cells
AID338776	Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids after 1 hr
AID332831	Antitumor activity against mouse solid EAC cells xenografted in ddY mouse at 7 mg/kg, ip qd for 3 to 8 days measured after 10 days relative to control
AID338778	Cytotoxicity against human Hep2 cells
AID338781	Cytotoxicity against mouse L5178Y cells
AID332826	Toxicity in ddY mouse xenografted with mouse solid Ehrlich carcinoma cells assessed as mortality at 20 mg/kg, ip qd for 3 to 8 days measured after 10 days
AID332833	Antitumor activity against mouse EAC cells xenografted in ddY mouse assessed as median survival time at 7 mg/kg, ip qd for 2 to 8 days
AID332828	Antitumor activity against mouse solid EAC cells xenografted in ddY mouse assessed as tumor weight at 20 mg/kg, ip qd for 3 to 8 days measured after 10 days
AID338772	Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids at 50 ug/ml after 1 hr
AID338773	Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids at 10 ug/ml after 1 hr
AID332830	Antitumor activity against mouse solid EAC cells xenografted in ddY mouse at 20 mg/kg, ip qd for 3 to 8 days measured after 10 days relative to control
AID332824	Cytotoxicity against human KB cells
AID332832	Antitumor activity against mouse EAC cells xenografted in ddY mouse assessed as median survival time at 20 mg/kg, ip qd for 2 to 8 days
AID338775	Antitumor promotor activity against mouse C3H10T1/2 cells assessed as inhibition of TPA-enhanced [3H]choline chloride incorporation in to phospholipids at 1.5 ug/ml after 1 hr
AID338777	Cytotoxicity against human KB cells
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.46 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.54 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.46)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
phloroglucinol Phloroglucinol: A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.. phloroglucinol : A benzenetriol with hydroxy groups at position 1, 3 and 5.	2.4	2	benzenetriol; phenolic donor	algal metabolite
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.05	1	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.05	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor

Condition	Relationship Strength	Studies
HIV Coinfection [description not available]	2.05	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	2.05	1
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	1.97	1

chemdatabank.com